1. At a Glance
Sanjivani Parenteral Ltd (SPL) is that pharma cousin at the family function who brags about being “export-oriented” but still borrows your pen to sign cheques. Market cap of ₹270 crore, stock price at ₹220 (down 30% in a year), book value a humble ₹32, and P/E a spicy 33x — it’s basically the small-cap pharma Tinder profile: great selfies (ROCE 30%, ROE 25%), but swipe left when you see the long-term cash conversion cycle. Sales stood at ₹71.6 crore in FY25 with a PAT of ₹8.1 crore. Returns are like your gym subscription — 5-year CAGR 88%, but short-term 1-year return -30%. The company screams “multibagger” on paper, but real life ka gym trainer bolta hai: “Sir, attendance bhi zaroori hai.”
2. Introduction
Ladies and gentlemen, welcome to the curious case of Sanjivani Parenteral Ltd — no relation to the TV serial Sanjivani where doctors did more romance than medicine, but still equally dramatic. Incorporated in 1994, this Navi Mumbai–Dehradun two-plant wonder makes injectables, tablets, capsules, and enough sterile powders to make Walter White proud.
Exports? 72%. Domestic? 28%. Region-wise? A perfect thali plate — Latin America 30%, Middle East 34%, India & Subcontinent 33%. CIS countries 3% — basically the garnish on top.
The company is WHO-GMP certified, which in pharma world is like saying “Mummy, see, teacher gave me a gold star.” It has tie-ups with the likes of Gland, Macleods, and Vitabiotics. But hold your applause — debtor days have exploded from 45 to 87. Matlab bech dete ho dawai, paisa aata hi nahi. Classic small-cap jugaad.
Promoters hold just 31%. Public is majority shareholder here. Bhai, jab retail investor promoter se zyada control rakhta hai, company ka AGM kabhi kabhi shaadi ka baraat lagta hai.
3. Business Model – WTF Do They Even Do?
SPL makes parenterals (fancy word for “injectables jab dawai ko stomach bypass karna ho”), tablets, nutraceuticals, and a few vitamin supplements for when you’re tired of ghar ka khana.
Revenue split is basically a thali without dessert: Injectables ~72%, Tablets ~27%, Nutraceuticals ~1% (haan, bas ek papad).
They produce:
- Tablets – 720 million annual capacity (enough to overdose an entire state).
- Ampoules – 84 million, because who doesn’t like a sharp poke.
- Liquid injectables – 12 million, a pharmacist’s Holi supply.
- B-Lactam capsules – 180 million, fight bacteria while burning a hole in your balance sheet.
Clients include Gland (injectables royalty), Macleods (mass-market pills), and Vitabiotics (those rainbow-coloured vitamins your mom forces).
So, in short: SPL manufactures for others, exports to the Middle East, and dreams of USFDA approval like every Indian pharma smallcap. Aapko lag
